Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning Ivosidenib & Biliary tract cancer / Cholangiocarcinoma (IDH1 m), FDA‑approved Ivosidenib for previously treated, unresectable locally advanced or metastatic Biliary tract cancer / Cholangiocarcinoma (IDH1 m), but there is no EMA marketing authorization for this indication as of November 2025 (1, 2)
Ivosidenib has been studied in patients with advanced Biliary tract cancer / Cholangiocarcinoma (IDH1 m). In a phase III study, ivosidenib demonstrated improved progression-free survival compared to placebo: Progressi…